Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis

Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis

Abstract: The application of allogeneic hematopoietic cell transplantation (allo-HCT) in non-Hodgkin lymphoma (NHL) patients ≥65 years in the United States is limited by lack of Medicare coverage for this indication. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) da...

Full description

Bibliographic Details
Main Authors: Nirav N. Shah, Kwang Woo Ahn, Carlos Litovich, Timothy S. Fenske, Sairah Ahmed, Minoo Battiwalla, Nelli Bejanyan, Parastoo B. Dahi, Javier Bolaños-Meade, Andy I. Chen, Stefan O. Ciurea, Veronika Bachanova, Zachariah DeFilipp, Narendranath Epperla, Nosha Farhadfar, Alex F. Herrera, Bradley M. Haverkos, Leona Holmberg, Nasheed M. Hossain, Mohamed A. Kharfan-Dabaja, Vaishalee P. Kenkre, Hillard M. Lazarus, Hemant S. Murthy, Taiga Nishihori, Andrew R. Rezvani, Anita D'Souza, Bipin N. Savani, Matthew L. Ulrickson, Edmund K. Waller, Anna Sureda, Sonali M. Smith, Mehdi Hamadani
Format: Article
Language:English
Published: Elsevier 2018-04-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952920310387

Internet

http://www.sciencedirect.com/science/article/pii/S2473952920310387

Similar Items